Announcements Trials
Browse Landscape

Status

Available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 25Observational 1Expanded_access 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Afatinib 3ceritinib 2Gefitinib 2zipalertinib 1zenocutuzumab 1ulixertinib 1trilaciclib 1telisotuzumab vedotin 1tazemetostat 1taletrectinib 1sotorasib 1selpercatinib 1rovalpituzumab tesirine 1rociletinib 1pralsetinib 1pegilodecakin 1patritumab deruxtecan 1osimertinib 1mobocertinib 1lorlatinib 1lazertinib 1epigallocatechin gallate 1ensartinib 1dabrafenib 1cemiplimab 1capmatinib 1brigatinib 1belagenpumatucel L 1balstilimab 1amivantamab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × ensartinib × Thoracic × Clear all
NCT04146571 2022-10-20

Expanded Access to Ensartinib for Participants With ALK+ NSCLC

Xcovery Holdings, Inc.

Available
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡